Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Case Rep ; 25: e942753, 2024 Jan 29.
Article in English | MEDLINE | ID: mdl-38282341

ABSTRACT

BACKGROUND Kimura disease is a rare, chronic inflammatory disorder typically presenting as a painless mass in the head or neck and associated with elevated serum immunoglobulin E and blood and tissue eosinophilia. Generally benign, its management is not well-defined, but corticosteroids are a common initial treatment. We detail a case of refractory Kimura disease successfully managed with CVP (Cyclophosphamide, Vincristine, Prednisone) chemotherapy and no recurrence during 6 rounds of treatment. CASE REPORT A 64-year-old woman, previously diagnosed with Kimura disease, returned to the hospital with upper eyelid ptosis. Upon examination, a solid mass was palpable in her left upper eyelid. Peripheral blood tests confirmed elevated IgE levels at 356.0 IU/ml. An excisional biopsy showed infiltration of lymphocytes and eosinophils, consistent with Kimura disease. Despite undergoing corticosteroid treatment, surgical debulking, radiation, and immunosuppressant therapy, her condition worsened. Concerns were raised due to imaging features suggestive of lymphoma, although no malignancy was evident in subsequent biopsies. It was decided to manage the disease using CVP chemotherapy, leading to significant symptom improvement. There have been no recurrences during the 12-month follow-up period. CONCLUSIONS Kimura disease is typically benign and responsive to treatment, but it often recurs and can progress. When symptoms are not controlled with conventional treatments, including corticosteroids, immunosuppressants, radiation, and surgical debulking, chemotherapy may be a reasonable option even when no definite signs of malignancy is identified. Further research is needed to explore the utility of CHOP and CVP in managing uncontrolled Kimura disease.


Subject(s)
Angiolymphoid Hyperplasia with Eosinophilia , Kimura Disease , Female , Humans , Middle Aged , Kimura Disease/drug therapy , Angiolymphoid Hyperplasia with Eosinophilia/diagnosis , Angiolymphoid Hyperplasia with Eosinophilia/drug therapy , Angiolymphoid Hyperplasia with Eosinophilia/pathology , Prednisone/therapeutic use , Vincristine/therapeutic use , Adrenal Cortex Hormones/therapeutic use
2.
Clin Exp Dermatol ; 49(5): 502-506, 2024 Apr 23.
Article in English | MEDLINE | ID: mdl-38149974

ABSTRACT

Kimura disease (KD) is a rare, chronic angiolymphoproliferative inflammatory disease appearing to be mostly restricted to the skin and soft tissue. Cutaneous involvement of KD includes head and/or neck nodules showing suggestive histological features, frequently associated with an atopic dermatitis-like or prurigo-like presentation. KD is challenging to treat, with high rate of recurrence using current therapeutic strategies. Evidence for involvement of a T-helper type 2 (Th2) immune response in KD pathogenesis has been found in previous studies. Consequently, this study aimed to determine the efficacy and safety of dupilumab, a human monoclonal antibody that inhibits signalling of key Th2 cytokines, interleukin (IL)-4 and IL-13, within a single-centre cohort of patients with cutaneous KD. Two adults with a diagnosis of refractory (failure of at least one treatment line) cutaneous-restricted KD based on clinical, biological, histological, molecular and imaging findings received dupilumab for KD, and showed dramatic response with a good safety profile.


Subject(s)
Antibodies, Monoclonal, Humanized , Kimura Disease , Humans , Antibodies, Monoclonal, Humanized/therapeutic use , Male , Adult , Kimura Disease/drug therapy , Kimura Disease/pathology , Middle Aged , Female , Treatment Outcome , Interleukin-4 , Interleukin-13/antagonists & inhibitors
3.
Immun Inflamm Dis ; 11(11): e1084, 2023 Nov.
Article in English | MEDLINE | ID: mdl-38018601

ABSTRACT

BACKGROUND: Kimura disease (KD) is a rare chronic inflammatory disorder involving the Th2 pathway. Although medical treatment with steroids or other immunosuppressants is available, they may cause developmental issues in the pediatric population. Surgical intervention has also been suggested; however, it is associated with high recurrence rates. CASE PRESENTATION: A 14-year-old boy presented with left retroauricular lymph node enlargement at the age of 5 years. At the age of 7 years, he was diagnosed with nephrotic syndrome which subsided after steroid treatment for approximately 6 years. The retroauricular lymph node was surgically excised, and KD was confirmed. However, recurrent enlargement of the left retroauricular and neck lymph nodes occurred after 2 years. Persistently high IgE levels and fluctuating eosinophil counts were observed following steroid treatment. Dupilumab was prescribed because of the difficulty in tapering the steroid dosage. A loading dose of 600 mg was administered, followed by a maintenance dose of 300 mg every 2 weeks. The IgE level decreased after 3 months, and a low eosinophil count was maintained after steroid discontinuation. Follow-up computed tomography revealed a decrease in the size of the lymph nodes with no side effects such as conjunctivitis. CONCLUSION: Traditional treatments have raised developmental concerns in the pediatric population and are associated with high recurrence rates. Dupilumab targets the Th2 pathway and provides effective results, with few adverse effects. Dupilumab may be a therapeutic option for KD and other diseases involving the Th2 pathway.


Subject(s)
Angiolymphoid Hyperplasia with Eosinophilia , Kimura Disease , Male , Humans , Child , Child, Preschool , Adolescent , Kimura Disease/complications , Kimura Disease/drug therapy , Angiolymphoid Hyperplasia with Eosinophilia/diagnosis , Angiolymphoid Hyperplasia with Eosinophilia/drug therapy , Angiolymphoid Hyperplasia with Eosinophilia/complications , Steroids/therapeutic use , Immunoglobulin E
4.
Front Immunol ; 13: 1084879, 2022.
Article in English | MEDLINE | ID: mdl-36591252

ABSTRACT

Kimura disease (KD) is a rare and benign chronic inflammatory disease of unknown cause. It is characterized by subcutaneous granuloma of soft tissues in the head and neck region, increased eosinophil count, and elevated serum IgE. Currently, no definitive treatments are recommended. A 57-year-old Chinese man was diagnosed with KD after 7 years of slow subcutaneous masses growth. The patient underwent treatment of oral glucocorticoids for 1 year, but the masses recurred as the dosage was tapered down. Subsequent anti-IgE therapy of omalizumab administered subcutaneously at 450 mg/day at a 4-week interval did not show improvement. The size of masses and serum IgE and circulating eosinophils did not decrease significantly after 19 cycles of continuous treatment. Ultimately, switched strategy of dupilumab was applied at an initial dose of 600 mg, followed by 300 mg every 2 weeks for 4 months. This treatment demonstrated dramatical effects with reduced masses in each area and fast dropdown of eosinophil counts, while the high level of serum IgE remained without changes. Recently, different biologics including anti-IgE, anti-IL-5, and anti-IL-4/IL-13 have been applied to treat KD with satisfied results and help to explore the pathogenesis of this rare disease. To our knowledge, this is the first report that demonstrates the effects of two different biologics in the same patient and reveals the impressive clinical efficacy of dupilumab to treat KD independent of IgE. Therefore, further investigation of the underlying mechanism and the development of diagnosis and treatment of KD is valuable.


Subject(s)
Biological Products , Kimura Disease , Male , Humans , Middle Aged , Kimura Disease/drug therapy , Antibodies, Monoclonal, Humanized/therapeutic use , Omalizumab/therapeutic use , Immunosuppressive Agents , Biological Products/therapeutic use
5.
BMC Nephrol ; 22(1): 241, 2021 06 30.
Article in English | MEDLINE | ID: mdl-34193062

ABSTRACT

BACKGROUND: Kimura's disease (KD) is a rare chronic inflammatory disease and the etiology remains uncharacterized. The typical manifestations are painless lymph node or subcutaneous masses. There is currently no report of prominent renal interstitial injury and cardiac insufficiency in KD. CASE PRESENTATION: A 45-year-old man was referred to our hospital with dark urine, subcutaneous masses in forehead and right retroauricular, multiple lymphadenopathy and unexplained cardiac insufficiency. Renal biopsy demonstrated eosinophilic interstitial nephritis. Laboratory tests revealed eosinophilia and a high level of serum IgE. A biopsy of cervical lymph node was performed and KD was diagnosed. Treatment with oral prednisone resulted in a decrease of eosinophil, serum IgE, improvement of cardiac function, and regression of the subcutaneous mass. CONCLUSIONS: We describe an extremely rare KD case presenting with eosinophilic interstitial nephritis, cardiac insufficiency and significant response to prednisone. The clinicians should improve the disease awareness and find optimal treatment.


Subject(s)
Eosinophilia/etiology , Heart Failure/etiology , Kimura Disease/complications , Kimura Disease/diagnosis , Nephritis, Interstitial/etiology , Anti-Inflammatory Agents/therapeutic use , Eosinophilia/drug therapy , Eosinophilia/pathology , Heart Failure/drug therapy , Humans , Kimura Disease/drug therapy , Kimura Disease/pathology , Lymph Nodes/pathology , Male , Middle Aged , Nephritis, Interstitial/drug therapy , Nephritis, Interstitial/pathology , Prednisone/therapeutic use
7.
BMJ Case Rep ; 14(1)2021 Jan 18.
Article in English | MEDLINE | ID: mdl-33461987

ABSTRACT

Kimura's disease is a rare, benign, chronic inflammatory disorder characterised by its eosinophilic infiltrate. Patients often present with one or more progressively enlarging subcutaneous lymph nodes in the head and neck region or enlarging salivary glands. We describe the case of a 26-year-old man presenting with severe peripheral eosinophilia and upper airway inflammatory symptoms, who later developed cervical lymphadenopathy and formally diagnosed with Kimura's disease. Based on our English-language MEDLINE literature search, to our knowledge this is the first case report describing treatment of Kimura's disease with mepolizumab.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Eosinophilia/drug therapy , Kimura Disease/drug therapy , Rhinitis/drug therapy , Sinusitis/drug therapy , Adult , Eosinophilia/complications , Eosinophilia/diagnosis , Humans , Kimura Disease/complications , Kimura Disease/diagnosis , Male , Rhinitis/complications , Rhinitis/diagnosis , Rhinitis/immunology , Sinusitis/complications , Sinusitis/diagnosis , Sinusitis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...